A focused review of study centric data – why and what’s new?

Over the past 30 years Cochrane has grown as a global network with a reputation for producing gold standard evidence syntheses. At the same time, the biomedical publishing field has grown too. We are making some big changes in 2023 to confirm our place as one of the world’s leaders in producing trusted health and social care evidence.

Reviews will be shorter. Users of evidence are best served by a more focused article, which also makes writing and updating them simpler. The main body of the review will contain sections that are most useful to users of Cochrane evidence, with a clearer distinction between the main article and supplementary materials. With a shorter review we are moving the structure to where it’s needed most: the data. This change is powered by moving to study centric data in RevMan. By improving the structure of data associated with Cochrane reviews, we can increase their impact by making it easier for policy makers, guideline developers and others to reuse our evidence.

In this webinar, Ella Flemyng (Interim Head of Editorial Policy and Research Integrity) and Gert van Valkenhoef (Head of IT Infrastructure and Development) will discuss these developments and the benefits for authors and users of Cochrane reviews.